EVOLVE104

EvolveImmune United, Inc · Phase 1 active Small molecule

At a glance

Generic name	EVOLVE104
Sponsor	EvolveImmune United, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EVOLVE104 CI brief — competitive landscape report
EVOLVE104 updates RSS · CI watch RSS
EvolveImmune United, Inc portfolio CI